CA1052820A - Aromatic ketones having cardiovascular activity - Google Patents
Aromatic ketones having cardiovascular activityInfo
- Publication number
- CA1052820A CA1052820A CA230,291A CA230291A CA1052820A CA 1052820 A CA1052820 A CA 1052820A CA 230291 A CA230291 A CA 230291A CA 1052820 A CA1052820 A CA 1052820A
- Authority
- CA
- Canada
- Prior art keywords
- hydroxy
- chloro
- product
- reacting
- general formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000008365 aromatic ketones Chemical class 0.000 title description 3
- 230000005792 cardiovascular activity Effects 0.000 title description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 28
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 13
- 239000002253 acid Substances 0.000 claims abstract description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 8
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 8
- 239000000460 chlorine Substances 0.000 claims abstract description 6
- 125000005843 halogen group Chemical group 0.000 claims abstract description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000011737 fluorine Substances 0.000 claims abstract description 5
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims abstract description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229910052794 bromium Inorganic materials 0.000 claims abstract description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims abstract description 3
- 125000003118 aryl group Chemical group 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 7
- KRIOVPPHQSLHCZ-UHFFFAOYSA-N propiophenone Chemical compound CCC(=O)C1=CC=CC=C1 KRIOVPPHQSLHCZ-UHFFFAOYSA-N 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 6
- JZEHWMUIAKALDN-UHFFFAOYSA-N 1-amino-3-phenoxypropan-2-ol Chemical class NCC(O)COC1=CC=CC=C1 JZEHWMUIAKALDN-UHFFFAOYSA-N 0.000 claims description 5
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 claims description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- OLVYYKLFIUGMCW-UHFFFAOYSA-N 1-(5-fluoro-2-hydroxyphenyl)propan-1-one Chemical compound CCC(=O)C1=CC(F)=CC=C1O OLVYYKLFIUGMCW-UHFFFAOYSA-N 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 3
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 claims description 3
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000012429 reaction media Substances 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 150000003141 primary amines Chemical class 0.000 claims 2
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 229940072033 potash Drugs 0.000 claims 1
- 235000015320 potassium carbonate Nutrition 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 15
- 150000007513 acids Chemical class 0.000 abstract description 5
- 230000003287 optical effect Effects 0.000 abstract description 5
- 150000003839 salts Chemical class 0.000 abstract description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract description 4
- 238000011282 treatment Methods 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 abstract 1
- DSNYFFJTZPIKFZ-UHFFFAOYSA-N propoxybenzene Chemical class CCCOC1=CC=CC=C1 DSNYFFJTZPIKFZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000000047 product Substances 0.000 description 18
- 239000000203 mixture Substances 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229960001317 isoprenaline Drugs 0.000 description 5
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 125000001033 ether group Chemical group 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- -1 3-tertiary-butyl-aminopropoxy Chemical group 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000011128 cardiac conduction Effects 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 208000021822 hypotensive Diseases 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229960003712 propranolol Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- NDXLYRKTHTZXRC-UHFFFAOYSA-N 1-(5-bromo-2-hydroxyphenyl)propan-1-one Chemical compound CCC(=O)C1=CC(Br)=CC=C1O NDXLYRKTHTZXRC-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002908 adrenolytic effect Effects 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- NLUNLVTVUDIHFE-UHFFFAOYSA-N cyclooctylcyclooctane Chemical compound C1CCCCCCC1C1CCCCCCC1 NLUNLVTVUDIHFE-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000001435 haemodynamic effect Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 150000002691 malonic acids Chemical class 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
- C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
- C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA310,907A CA1061801A (en) | 1974-06-28 | 1978-09-08 | Preparation of aromatic ketones having cardiovascular activity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB28925/74A GB1501632A (en) | 1974-06-28 | 1974-06-28 | Aromatic ketones having cardiovascular activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1052820A true CA1052820A (en) | 1979-04-17 |
Family
ID=10283421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA230,291A Expired CA1052820A (en) | 1974-06-28 | 1975-06-27 | Aromatic ketones having cardiovascular activity |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US4252825A (enExample) |
| JP (2) | JPS5826743B2 (enExample) |
| AR (1) | AR205388A1 (enExample) |
| AT (1) | AT343098B (enExample) |
| BE (1) | BE830766A (enExample) |
| CA (1) | CA1052820A (enExample) |
| CS (1) | CS197248B2 (enExample) |
| DE (1) | DE2528147A1 (enExample) |
| DK (1) | DK143555C (enExample) |
| ES (1) | ES438931A1 (enExample) |
| FR (1) | FR2276032A1 (enExample) |
| GB (1) | GB1501632A (enExample) |
| IE (1) | IE41386B1 (enExample) |
| NL (1) | NL7507703A (enExample) |
| SE (2) | SE416546B (enExample) |
| YU (1) | YU165775A (enExample) |
| ZA (1) | ZA754141B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1501632A (en) * | 1974-06-28 | 1978-02-22 | Cm Ind | Aromatic ketones having cardiovascular activity |
| JPH0516363Y2 (enExample) * | 1986-08-01 | 1993-04-28 | ||
| KR100668539B1 (ko) | 2002-08-19 | 2007-01-16 | 화이자 프로덕츠 인크. | 과증식성 질환에 대한 조합요법 |
| CA2526730A1 (en) * | 2003-05-30 | 2004-12-09 | Ranbaxy Laboratories Limited | Substituted pyrrole derivatives |
| US20050037063A1 (en) * | 2003-07-21 | 2005-02-17 | Bolton Anthony E. | Combined therapies |
| GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| JP2009514851A (ja) * | 2005-11-08 | 2009-04-09 | ランバクシー ラボラトリーズ リミテッド | （３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法 |
| US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| WO2008020314A2 (en) * | 2006-03-14 | 2008-02-21 | Ranbaxy Laboratories Limited | Statin stabilizing dosage formulations |
| AR063469A1 (es) * | 2006-07-14 | 2009-01-28 | Ranbaxy Lab Ltd | Formas polimorficas de ácido (3r,5r)-7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]-pirrol-1-il]-3, 5-dihidroxi-heptanoico, sal hemicalcio, metodos de preparacion de las mismas, una composicion farmaceutica que las comprende y su uso en el tratamiento de enfermedades |
| WO2008070496A2 (en) | 2006-12-01 | 2008-06-12 | Bristol-Myers Squibb Company | N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
| BR112015026513A2 (pt) | 2013-04-17 | 2017-07-25 | Pfizer | derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares |
| WO2016055901A1 (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds |
| MA54261B1 (fr) | 2019-01-18 | 2025-03-28 | Astrazeneca Ab | Inhibiteurs de pcsk9 et leurs procédés d'utilisation |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL301580A (enExample) * | 1962-12-11 | |||
| US3637852A (en) * | 1963-08-26 | 1972-01-25 | Boehringer Sohn Ingelheim | 1-phenoxy-2-hydroxy-3-isopropylamino-propanes and salts thereof |
| DE1493454C3 (de) * | 1963-08-26 | 1980-04-30 | C.H. Boehringer Sohn, 6507 Ingelheim | 1 -Aryloxy^-hydroxy-S-isopropylaminopropane und deren Salze sowie deren Herstellung und darauf basierende Arzneimittel |
| GB1231783A (en) * | 1967-05-16 | 1971-05-12 | May & Baker Ltd | Benzene derivatives |
| JPS512115B2 (enExample) * | 1971-09-28 | 1976-01-23 | ||
| JPS4911847A (enExample) * | 1972-05-20 | 1974-02-01 | ||
| GB1501632A (en) * | 1974-06-28 | 1978-02-22 | Cm Ind | Aromatic ketones having cardiovascular activity |
-
1974
- 1974-06-28 GB GB28925/74A patent/GB1501632A/en not_active Expired
-
1975
- 1975-01-01 AR AR259407A patent/AR205388A1/es active
- 1975-06-20 FR FR7519386A patent/FR2276032A1/fr active Granted
- 1975-06-24 IE IE1395/75A patent/IE41386B1/xx unknown
- 1975-06-24 DE DE19752528147 patent/DE2528147A1/de not_active Withdrawn
- 1975-06-24 CS CS754483A patent/CS197248B2/cs unknown
- 1975-06-26 SE SE7507359A patent/SE416546B/xx unknown
- 1975-06-27 ZA ZA00754141A patent/ZA754141B/xx unknown
- 1975-06-27 CA CA230,291A patent/CA1052820A/en not_active Expired
- 1975-06-27 NL NL7507703A patent/NL7507703A/xx not_active Application Discontinuation
- 1975-06-27 YU YU01657/75A patent/YU165775A/xx unknown
- 1975-06-27 ES ES438931A patent/ES438931A1/es not_active Expired
- 1975-06-27 BE BE157788A patent/BE830766A/xx not_active IP Right Cessation
- 1975-06-27 AT AT497275A patent/AT343098B/de not_active IP Right Cessation
- 1975-06-27 DK DK292475A patent/DK143555C/da not_active IP Right Cessation
- 1975-06-28 JP JP50080469A patent/JPS5826743B2/ja not_active Expired
-
1978
- 1978-12-08 SE SE7812646A patent/SE417087B/sv unknown
-
1979
- 1979-01-05 US US06/001,314 patent/US4252825A/en not_active Expired - Lifetime
-
1980
- 1980-03-12 US US06/129,730 patent/US4302601A/en not_active Expired - Lifetime
-
1983
- 1983-01-07 JP JP58001033A patent/JPS5929574B2/ja not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| SE7812646L (sv) | 1978-12-08 |
| FR2276032B1 (enExample) | 1979-08-10 |
| AU8256675A (en) | 1977-01-06 |
| JPS58140050A (ja) | 1983-08-19 |
| US4252825A (en) | 1981-02-24 |
| SE416546B (sv) | 1981-01-19 |
| JPS5826743B2 (ja) | 1983-06-04 |
| ES438931A1 (es) | 1977-05-16 |
| AT343098B (de) | 1978-05-10 |
| SE7507359L (sv) | 1975-12-29 |
| JPS5123233A (en) | 1976-02-24 |
| FR2276032A1 (fr) | 1976-01-23 |
| BE830766A (fr) | 1975-12-29 |
| DK143555C (da) | 1982-02-01 |
| DK143555B (da) | 1981-09-07 |
| JPS5929574B2 (ja) | 1984-07-21 |
| DK292475A (da) | 1975-12-29 |
| GB1501632A (en) | 1978-02-22 |
| YU165775A (en) | 1982-02-28 |
| AR205388A1 (es) | 1976-04-30 |
| IE41386B1 (en) | 1979-12-19 |
| IE41386L (en) | 1975-12-28 |
| ATA497275A (de) | 1977-09-15 |
| ZA754141B (en) | 1976-06-30 |
| US4302601A (en) | 1981-11-24 |
| SE417087B (sv) | 1981-02-23 |
| NL7507703A (nl) | 1975-12-30 |
| DE2528147A1 (de) | 1976-01-15 |
| CS197248B2 (en) | 1980-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1052820A (en) | Aromatic ketones having cardiovascular activity | |
| US4194009A (en) | Aryloxyphenylpropylamines for obtaining a psychotropic effect | |
| US4314081A (en) | Arloxyphenylpropylamines | |
| US4018895A (en) | Aryloxyphenylpropylamines in treating depression | |
| US4626549A (en) | Treatment of obesity with aryloxyphenylpropylamines | |
| US3873600A (en) | Phenoxycarbamates | |
| SU1632370A3 (ru) | Способ получени производных феноксиуксусной кислоты или их фармакологически приемлемых солей в форме рацемата или оптически-активного изомера | |
| US4311708A (en) | Phenol ethers | |
| US3712927A (en) | Alkanolamine derivatives | |
| US3341594A (en) | 1-(3, 5-dihydroxy-phenyl)-1-hydroxy-2-isopropylamino-ethane and salts thereof | |
| US4228187A (en) | Alkyl and cycloalkylthiophenylalkylaminoalkanols, their salts and the preparation thereof | |
| JPH021442A (ja) | ２―（２‐ヒドロキシ‐３‐フエノキシプロピルアミノ）エチルフエノキシアセトアミド化合物、その製法、この化合物を含む肥満症及び関連症治療剤並びに中間体 | |
| EP0047536B1 (en) | Substituted propylamines | |
| GB2106105A (en) | Benzo-heterocycles | |
| US3674840A (en) | 1-(para-alkoxyalkoxy-phenyl)-2-hydroxy-3-alkylaminopropanes and the salts thereof | |
| US3634511A (en) | 1-(4-acylamino-2-alkylphenoxy)-3-amino-2-propanol derivatives | |
| CA1123458A (en) | Alkanolamine derivatives | |
| US3873620A (en) | Phenoxyalkylamines, process for their preparation and applications thereof | |
| Mull | Thionocarbanilates with anthelmintic activity | |
| US4835315A (en) | Fluorophenacyl-amine derivatives and application thereof in therapeutics | |
| EP0139921B1 (en) | 2-phenylethylamine derivatives | |
| US3856951A (en) | Substituted benzoic acid hypoliphemic agents | |
| US4201790A (en) | Benzophenone derivatives | |
| CA1061801A (en) | Preparation of aromatic ketones having cardiovascular activity | |
| US4003936A (en) | 2-Hydrocinnampyl-1,3-cyclopentanediones |